Want to see TNGX full AI Analyst Report?
Total Valuation
Tango Therapeutics has a market cap or net worth of $4.31B. The enterprise value is $3.70K.
Market Cap$4.31B
Enterprise Value$3.70K
Share Statistics
Tango Therapeutics has 168,610,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding168,610,370
Owned by Insiders9.39%
Owned by Institutions11.42%
Financial Efficiency
Tango Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -29.31%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-29.31%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee455.36K
Profits Per Employee-741.56K
Employee Count137
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tango Therapeutics is ―. Tango Therapeutics’s PEG ratio is 0.38.
PE Ratio―
PS Ratio16.50
PB Ratio2.97
Price to Fair Value2.97
Price to FCF-7.36
Price to Operating Cash Flow-26.72
PEG Ratio0.38
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 62.38M and earned -101.59M in profits. Earnings per share was -0.87.
Revenue62.38M
Gross Profit60.10M
Operating Income-111.29M
Pretax Income-101.59M
Net Income-101.59M
EBITDA-99.31M
Earnings Per Share (EPS)-0.87
Cash Flow
In the last 12 months, operating cash flow was -143.90M and capital expenditures -373.00K, giving a free cash flow of -144.27M billion.
Operating Cash Flow-143.90M
Free Cash Flow-144.27M
Free Cash Flow per Share-0.86
Dividends & Yields
Tango Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change278.88%
50-Day Moving Average28.54
200-Day Moving Average18.31
Relative Strength Index (RSI)41.82
Average Volume (3m)4.03M
Important Dates
Tango Therapeutics upcoming earnings date is Nov 10, 2026, Before Open (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Tango Therapeutics as a current ratio of 16.32, with Debt / Equity ratio of 3.12%
Current Ratio16.32
Quick Ratio16.32
Debt to Market Cap0.03
Net Debt to EBITDA0.79
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tango Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Tango Therapeutics EV to EBITDA ratio is -9.57, with an EV/FCF ratio of -6.79.
EV to Sales15.24
EV to EBITDA-9.57
EV to Free Cash Flow-6.79
EV to Operating Cash Flow-6.84
Balance Sheet
Tango Therapeutics has $1.01B in cash and marketable securities with $31.99M in debt, giving a net cash position of $982.00M billion.
Cash & Marketable Securities$1.01B
Total Debt$31.99M
Net Cash$982.00M
Net Cash Per Share$5.82
Tangible Book Value Per Share$2.98
Margins
Gross margin is 98.25%, with operating margin of -178.39%, and net profit margin of -162.85%.
Gross Margin98.25%
Operating Margin-178.39%
Pretax Margin-162.85%
Net Profit Margin-162.85%
EBITDA Margin-159.19%
EBIT Margin-162.85%
Analyst Forecast
The average price target for Tango Therapeutics is $43.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.42
Price Target Upside63.04% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast121.47%
EPS Growth Forecast36.95%